BioSpace News Archive

Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the presentation of new clinical data on SRF388, a potential first-in-class IL-27 antibody.

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced positive results from the registration-enabling Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib 600 mg BID in patients with non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation who have received at least one prior systemic therapy.

CASI Pharmaceuticals, Inc. announced it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to implement a 1-for-10 reverse stock split that will become effective at 5:00 p.m., Eastern Time, on June 1, 2022.

Oncocyte Corporation (Nasdaq: OCX), announced today new data from ongoing clinical research evaluating the utility of DetermaIO™, the Company’s proprietary test designed to determine the likelihood of benefit of immune checkpoint inhibitors (ICIs), at the upcoming American Society of Clinical Oncology Annual Meeting.

Adagene Inc., a company transforming the discovery and development of novel antibody-based therapies, announced the publication of data showing the potential best-in-class safety profile of its anti-CTLA-4 monoclonal antibody, ADG126.

Affimed N.V. announced that three abstracts of clinical trial designs of its AFM24 innate cell engager have been published and will be presented at the American Society of Clinical Oncology Annual Meeting, taking place on June 3-7, 2022 in Chicago, IL.

Elevar Therapeutics, Inc. announced its Phase 2 clinical trial evaluating rivoceranib, an orally administered tyrosine kinase inhibitor, demonstrated clinical effectiveness in patients with progressive recurrent or metastatic adenoid cystic carcinoma.

Mereo BioPharma Group plc announced the presentation of interim clinical data from its Phase 1b/2 Study of Etigilimab and Nivolumab in Subjects with Select Locally Advanced or Metastatic Solid Tumors in a poster at the 2022 American Society of Clinical Oncology Annual Meeting taking place June 3 – 7, 2022 in Chicago IL.

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing therapies that combine both targeted and immune-mediated mechanisms, today announced positive results from its Phase 1 clinical trial of TPST-1120, a first-in-class1 PPARα antagonist, as a single agent and in combination with nivolumab in patients with advanced solid tumors.

IRADIMED CORPORATION, announced that John Glenn has been appointed Chief Financial Officer effective on or before June 20, 2022.